• Vitaspring Biomedical posted a net loss of USD 142,518 for the quarter ended Oct. 31, 2025, narrowing from the prior-year quarter.
• Operating loss widened to USD 135,733 as operating expenses rose to USD 135,733 from USD 117,927.
• Revenue was unchanged at no revenue as it continued restructuring its commercial strategy and evaluating supplier and regulatory considerations.
• For the nine months ended Oct. 31, net loss narrowed to USD 333,904 from USD 631,785 on lower operating expenses of USD 303,947 versus USD 553,420.
• Working capital deficiency widened to USD 4.36 million as of Oct. 31, with cash of USD 1,960 and current liabilities of USD 4.37 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vitaspring Biomedical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001077), on June 17, 2026, and is solely responsible for the information contained therein.